Optimal control of interferon-γ and tumor necrosis factor-α by interleukin-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction

Transplantation

Volumn 61, Issue 3, 1996, Pages 497-502

  Toungouz, Michel ^a,c   Denys, Chantal ^a   De Groote, Donat ^b   Andrien, Marc ^a   Dupont, Etienne ^a  

^a ERASME HOSPITAL   (Belgium)

^b Medgenix Grp R and D   (Belgium)

^c FUND FOR SCIENTIFIC RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD TRANSFUSION REACTION; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOREGULATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTIBODIES, BLOCKING; BLOOD TRANSFUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEEDBACK; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LYMPHOCYTE CULTURE TEST, MIXED; NEUTRALIZATION TESTS; TRANSPLANTATION IMMUNOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030067018     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602150-00031     Document Type: Article

References (28)

1. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin 10. Annu Rev Immunol 1993; 11: 165.
2. Bejarano M-T, de Waal Malefyt R, Bigler M, et al. Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol 1993; 12: 1389.
3. Tadmori W, Zhang M, Beavis AJ, Sullivan LM, Narula SK. Suppression of the allogeneic reponse by human IL-10: a critical role for suppression of a synergy between IL-2 and TNF-α. Cytokine 1994; 6: 462.
4. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
5. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2371.
6. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin-10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041.
7. Holler F, Roncarolo MG, Hintermeier-Knabe R, et al. Low incidence of transplant related complications in patients with high spontaneous cellular IL-10 production prior to conditioning: evidence for a protective role of IL-10 in allogeneic bone marrow transplantation [Abstract]. Bone Marrow Transplant 1995; 15 (suppl 2): S59.
8. Bachetta R, Bigler M, Touraine J-L, et al. High levels of interleukin 10 production in vivo are associated with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493.
9. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like cells in peripheral tolerance. Transplantation 1992; 53: 1281.
10. Wang L, Goillot E, Tepper RI. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell Immunol 1994; 159: 152.
11. Smith SR, Terminelli C, Pennline KJ, Kenworthy-Bott L, Donkin J, Calzetta A. Inhibitory effects of recombinant human interleukin 10 on disease manifestations in A P->F1 model of acute graft versus disease. Transplantation 1995; 59: 890.
12. Yssel H, de Waal Malefyt R, Roncarolo MG, et al. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 1992; 149: 2378.
13. Marchant A, Devière J, Byl B, De Groote D, Vincent JL, Goldman M. Interleukin-10 production during septicaemia. Lancet 1994; 343: 707.
14. van der Poll T, Jansen J, Levi M, ten Cate H, Wouter ten Cate J, van Deventer SJH. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180: 1985
15. Danzer SG, Kirchner H, Rink L. Cytokine interactions in human mixed lymphocyte culture. Transplantation 1994; 57: 1638.
16. Toungouz M, Denys C, Andrien M, De Groote D, Dupont E. IL-12 unmasks HLA class I differences during MLR induced IFN-γ production. Hum Immunol (in press).
17. Toungouz M, Denys C, Andrien M, De Groote D, Dupont E. Tumor necrosis factor-α and interleukin-6 production induced by variations of DR4 polymorphism during primary mixed lymphocyte reaction. Transplantation 1994; 58: 1393.
18. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145.
19. Chomarat P, Rissoan M-C, Banchereau J, Miossec P. Interferon-γ inhibits interleukin-10 production by monocytes. J Exp Med 1993; 177: 523.
20. Wanidworanun C, Strober W. Predominant role tumor necrosis factor-α in human IL-10 synthesis. J Immunol 1993; 151: 6853.
21. Toungouz M, Denys C, De Groote D, Andrien M, Dupont E. Alloactivation induced during mixed lymphocyte reaction provokes release of tumor necrosis factor α and interleukin-6 by macrophages and primes them to lipopolysaccharides. Hum Immunol 1993; 38: 221.
22. Lagaaij EL, Hennemann PH, Ruigrok M, et al. Effect of one HLA-DR-antigen-matched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989; 321: 702.
23. van der Mast BJ, Hornstra N, Ruigrok MB, Class FHJ, van Rood JJ, Lagaaij EL. Transfusion-associated graft-versus-host disease in immunocompetent patients: a self-protective mechanism. Lancet 1994; 343: 753.
24. Sasportes M, Fradelizi D, Dausset J. HLA-DR specific human suppressor lymphocytes generated by repeated in vitro sensitisation against allogeneic cells. Nature 1978; 276: 502.
25. Engelman EG, McMichael AJ, McDevitt HO. Suppression of the mixed lymphocyte reaction in man by a soluble T-cell factor. J Exp Med 1978; 147: 1037.
26. Sasportes M, Wolman E, Cohen D, et al. Suppression of the human allogeneic response in vitro with primed lymphocytes and suppressive supernates. J Exp Med 1980; 152: 270S.
27. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction: regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152: 1004.
28. Sad S, Marcotte R, Mosmann TR. Cytokine-induced differentiation of precursor mouse CD8+ cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271.